Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

- PMLiVE

Undeterred by aducanumab failure, Eisai and Biogen plough on

Investors sceptical, though mechanism different

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

- PMLiVE

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Bayer axes 1,250 pharma jobs, with R&D taking the brunt

Part of massive layoff of 12,000 people across conglomerate

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

Bayer symbol

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

A first for Loxo, and a second mutation-based targeted drug

- PMLiVE

Astellas makes another gene therapy play with Juventas deal

Targeting faecal incontinence, which affects 50m worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links